JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

Healthcare giant Pfizer ( PFE 2.24%) has been offering a high yield for some time. But that hasn't been enough to get ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Jim Cramer has discussed pharma giant Pfizer Inc. (NYSE:PFE) ...

Wyeth was a bigger deal, but with Pfizer's payout ratio so high, there isn't much wiggle room for the dividend. In other ...

(NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus ...

Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times.